

Amira Pharmaceuticals, Inc.

Founded in 2005: \$28 Million Invested; Seven Novel Lead Compounds Discovered

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory diseases.


Our research and development focus offers tremendous potential to identify novel, high-value therapies addressing a wide range of diseases and disorders triggered by inflammation, including asthma, cardiovascular and fibrotic diseases.

Amira combines the rigorous research of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions.


Our Pipeline

The scientific team at Amira is responsible for an impressive portfolio of compounds, oral, next-generation inhibitors of 5-lipoxygenase-activating protein (FLAPi), antagonists of the DP2 receptor (DP2), and antagonists of the LPA1 receptor (LPA).

Since the company's founding in 2005, Amira's has discovered seven, highly-targeted, novel compounds.



Company Milestones



Amira's Management Team

Amira's founders were pivotal to the discovery of several high-profile and successful clinical compounds, including Arcoxia[®], Singulair[®] and Vioxx[®]. This track record, combined with Amira's focus on identifying high-value compounds within bioactive lipid pathways, has enabled Amira to generate significant financial resources and early successes in discovery.

Robert Baltera, Jr., M.S., M.B.A. **Chief Executive Officer**



Robert Baltera is a seasoned pharmaceutical industry executive, who acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. Before becoming Amira's CEO, Bob held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing.

A scientist by training, Bob joined Amgen at the beginning of his career as a research associate but quickly moved to the operations side of the business, working in finance, product development and commercial operations. He successfully used his collective experience to serve as team leader responsible for the approval of Kineret[®] in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.

Bob has a master's of business administration from the Anderson School at UCLA and earned his bachelor's degree in microbiology and a master's degree in genetics from The Pennsylvania State University.

Peppi Prasit, Ph.D. **Chief Scientific Officer; Co-founder**



Peppi Prasit has more than 20 years of experience in pharmaceutical research and management. Prior to Amira Pharmaceuticals, he held various positions with Merck including head of chemistry at the Merck's San Diego facility. While at Merck, Peppi was the lead scientist responsible for Vioxx[®] and Arcoxia[®] and was involved in the optimization program that led to Singulair[®].

During his career, Peppi has led or contributed to research resulting in more than 65 published papers exploring various elements of drug discovery. Among other numerous research achievements, Peppi was part of a group that discovered potent, orally active CysLT1 antagonists, cathepsin K inhibitors and a FLAP inhibitor that went into clinic. He holds more than 30 granted patents.

Peppi received his Ph.D. in organic chemistry from Victoria University of Wellington in New Zealand and served as a post-doctoral fellow in organic and organometallic chemistry at Princeton University in New Jersey.

Amira's Management Team

Hari Kumar, Ph.D. **Chief Business Officer**



Hari Kumar brings to Amira almost 20 years of big pharmaceutical experience. Hari spent a total of 17 years at Hoffmann-La Roche, where he began his career in basic research, moved to sales and marketing, lifecycle management, and finally, business development. In 1996, Hari moved to Eisai Ltd, where he served as the company's European Marketing Director before returning to Roche in 1999.

During his career, Hari has overseen the launches of the immunosuppressive CellCept®, the Alzheimer's drug Aricept® and the gastric ulcer drug Aciphex®. He was also involved in guiding cross-functional teams at Roche for the transplantation franchise, during which time the products in the franchise achieved billion dollar sales. In his role as lead in-licensing manager for inflammation at Roche, Hari identified and partnered valuable products that significantly enhanced Roche's global portfolio. He was instrumental in securing partnerships with Isotechnika, Biotie, Biocryst and Actellion. Experience in almost all aspects of the pharmaceutical industry has given Hari a unique understanding of the elements that contribute to a successful drug.

Hari trained as an immunologist at University College London, where he completed his Ph.D. under the supervision of Professor N A Mitchison. Hari then completed post-doctoral fellowships at Tufts New England Medical Center in Boston and at the Marie Curie Cancer Research Centre in the United Kingdom.

Michael V. Swanson, M.B.A. **Chief Financial Officer**



Michael Swanson has over 30 years of experience in finance and accounting, including 17 years of CFO-level experience in life sciences and specialty pharmaceutical companies. Prior to joining Amira, Mike was the CFO of Prometheus Laboratories Inc., a privately-held specialty pharmaceutical company which sells both pharmaceutical products and diagnostic testing services for gastrointestinal diseases and disorders. During his time at Prometheus, Mike led several financings totaling over \$200 million dollars and, most recently, led the filing of a registration statement for Prometheus' initial public offering. Prior to Prometheus, Mike was the CFO of Advanced Tissue Sciences, Inc. where his responsibilities included the financing of this publicly-held, life sciences company.

Mike holds an MBA from the University of Southern California.

Amira's Management Team

Isabelle DeArmond, M.D., Ph.D.*
Vice President, Clinical Development



Isabelle DeArmond has more than 20 years of experience in the pharmaceutical industry. Before joining Amira Pharmaceuticals, she was the respiratory clinical research liaison for Roche Palo Alto in California. In this role, she led efforts to build a respiratory portfolio, developed clinical plans for new chemical entities, prepared submissions for investigational new drug (INDs), and evaluated licensing opportunities.

Isabelle obtained her medical degree and specialty in allergy immunology from the Medical School of the University of Paris (France) in 1983 and 1987, respectively. She started her career in the pharmaceutical industry conducting clinical evaluation of immune response modifiers. She then joined Rhone Poulenc Rorer to register an antihistamine and became the leader for the respiratory inflammation clinical group, with Azmacort® and Nasacort® as the main marketed products. She also developed expertise in pharmacoeconomics and the integration of quality of life measures in the development of new products. In 1998, Isabelle moved to Bristol Myers Squibb, in Princeton, NJ, where she worked on inflammation and dermatology compounds.

Isabelle has global experience in both early and late clinical development. Over the course of her career, she played an instrumental role in five drug approvals, and multiple INDs. She has also authored numerous expert reports as part of European registration dossiers.

*formerly, Isabelle Raizon-Ounis

Board of Directors

Bradley Bolzon, Ph.D.

Versant Ventures

Robert Baltera, JR., M.B.A.

Amira Pharmaceuticals

Dennis M Fenton, Ph.D.

Independent Member

Stephen W. Kaldor, Ph.D.

Independent Member

Kevin Kinsella, B.S., M.A.

Avalon Ventures

Heath Lukatch, Ph.D.

Novo A/S

David Schnell, M.D.

Prospect Venture Partners

Investors

Avalon Ventures

Novo A/S

Prospect Venture Partners

Versant Ventures

Areas of Focus

Inflammation

Respiratory diseases

Cardiovascular disease

Fibrotic Diseases

Cancer

Contact
Amira Pharmaceuticals
9535 Waples Street, Suite 100
San Diego, CA 92121
Phone: (858) 228-4650
Fax: (858) 558-8445
info@amirapharm.com